PURA Record 2018 Cannabis Beverages Sales Growth Gets Boost From KALY Partnership In 2019
April 16 2019 - 1:31PM
InvestorsHub NewsWire
PURA Record 2018 Cannabis Beverages
Sales Growth Gets Boost From KALY Partnership In 2019
Dallas, TX -- April 16, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) today reported over 350% year to year growth
between 2017 and 2018. The Company filed its annual financial
statement reporting over $1.2 million in revenue for year-end
December 31, 2018 with over $500,000 in net profit.
Management attributes the more than 350% revenue growth to the
success of the company’s EVERx CBD Sports Beverage. With the company’s recently
reported enhanced partnership with Kali-Extracts, (USOTC:
KALY) (“KALY”), management expects cannabis beverage
diversification and continued rapid growth in 2019. On
Friday, this week, April 19th, 2019, PURA management
will publish an online shareholder report with more details and
insight on the company’s 2018 growth and ongoing anticipated growth
in 2019. The online report is expected to include updates on
PURA’s work with KALY to produce new
beverages.
PURA is also working closely with the
company’s co-packer/partner Alkame Holdings, (USOTC:
ALKM) to expand production capacity and keep up with PURA’s
growing sales. PURA is also working with North American
Cannabis Holdings, (aka USMJ) (USOTC:
USMJ) to update PURA’s distribution channels to keep up with
USMJ’s online retail sales at USMJ.com and simultaneously meet wholesale
demand. The presentation scheduled for this Friday will also
include updates on PURA’s work with ALKM and
USMJ.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024